Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 15 February, 2012 and appeared in  CKD and NephrologyIssue 613

Kidney Failure Follows Metabolic Pathway

A protein kinase known as ROCK1 can exacerbate an important process called fission in the mitochondria, the power plants of cells, leading to diabetic kidney disease....

Advertisement

"We have shown the connection between ROCK1 (Rho-associated coiled-coil containing protein kinase) and the progression to kidney disease through the effect of ROCK1 on the mitochondria," said Dr. Farhad R. Danesh, associate professor of medicine – nephrology. "We have known that mitochondrial dysfunction plays a major role in the complications of diabetes, especially when affecting the eyes and kidneys. What we did not know was why people with diabetic complications develop mitochondrial dysfunction."

An estimated 15 million people in the United States have diabetes and 30 percent of them are at risk of developing kidney disease, one of its most serious complications. Such a major complication takes a human toll in suffering and an economic one in the cost of dialysis and kidney transplantation. Understanding the cellular changes that lead to kidney disease in diabetic patients might help researchers develop ways to prevent or delay such problems, said Danesh.

The mitochondria is known as the powerhouse of the cell, but it is also a dynamic organelle that plays important roles in cellular dynamics through processes known as mitochondrial fusion and fission. Danesh and his colleagues studied the effects of ROCK1 on the mitochondria in two mouse models of diabetes that lacked ROCK1 and another that had a form of the enzyme.

What they found was that when ROCK1 is activated, the mitochondria became fragmented in diabetic mice. This fragmentation leads to a process called apoptosis or programmed cell death.

Activation of ROCK1 means that another protein known as DRP-1 (dynamin-related protein 1) becomes activated and goes to the mitochondria, sparking fission. Mitochondrial fission is physiologically important in cell division, ensuring that each resulting cells has mitochondria.

However, pathological mitochondrial fission leads to cell death. The elucidation of this pathway can explain the road kidney cells follow to develop kidney disease in diabetes.

"These studies were done in mice, and we cannot be sure how they translate to humans," said Danesh. "However, we believe they do explain the metabolic pathway involved in diabetic kidney disease."

Cell Metabolism, 8 February, 2012 Volume 15, Issue 2
Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 15 February, 2012 and appeared in  CKD and NephrologyIssue 613

Past five issues: Diabetes Clinical Mastery Series Issue 85 | Issue 626 | Special Edition - Getting Patients on Track | Diabetes Clinical Mastery Series Issue 84 | Issue 625 |

2012 Most Popular Articles:

ADA/EASD Issue New Hyperglycemia Management Guidelines
Posted April 26, 2012
Type 2 More Dangerous in Children
Posted May 03, 2012
It’s the Variety of Fruit-and-Veggie That Lower Diabetes Risk
Posted May 03, 2012
Questioning Carbohydrate Restriction in Diabetes Management
Posted May 18, 2012
Ultra-Long-Acting Insulin Degludec, Two New Studies
Posted April 26, 2012
Eating Low Glycemic Index Foods at Breakfast Can Control Blood Sugar throughout the Day
Posted April 18, 2012
Metformin May Treat a Leading Cause of Blindness
Posted May 10, 2012
A Candy Treatment that Fights Diabetes and May Replace TZD's?
Posted May 10, 2012
Metformin May Not Be the Golden Pill After All for Treating Type 2 Diabetes
Posted April 18, 2012
Doubts Over Long Term Effectiveness of Group Education for Diabetes Patients
Posted May 03, 2012

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Marilyn Porter, RD, CDE | Melissa Diane Smith | Paul Chous, M.A., OD | Philip A. Wood PhD | Sheri R. Colberg PhD | Sherri Shafer | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Now that once-weekly GLP-1 is available, which product are you recommending for your type 2 patients?

Navigate Diabetes In Control
Announcement:



Search Articles On Diabetes In Control